PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Peginterferon→

Peginterferon PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
215647-85-1
Molecular formula
Not available
Molecular weight
~40000 g/mol
Drug class
Pegylated interferon alfarecombinant cytokine immunomodulator and antiviral agent
Mechanism of action
A covalent conjugate of recombinant interferon alfa and polyethylene glycol. Binding to cell-surface interferon receptors triggers JAK-STAT signalling and transcription of interferon-stimulated genes, producing antiviral, antiproliferative and immunomodulatory effects. PEG conjugation reduces clearance and prolongs systemic exposure.
Indications / reported uses
  • The term peginterferon covers multiple subtype-specific products (for example peginterferon alfa-2a and alfa-2b) with distinct labels. Depending on the subtype and product, indications have included chronic hepatitis B or C and selected myeloproliferative neoplasms; use the exact peginterferon product label for clinical indications.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys · https://www.ema.europa.eu/en/documents/product-information/pegintron-epar-product-information_en.pdf · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/peginterferon-alfa-2a · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Peginterferon PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Peginterferon Permitted Daily Exposure (PDE) report (the Peginterferon PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Peginterferon Occupational Exposure Limit (OEL) report (the Peginterferon OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.